Speaker Name: Prof. William McEvoy, Professor, Preventive Cardiology, NUI Galway Consultant Cardiologist, University Hospital Galway, Ireland.

Explore this expert session to:

• Understand SPRINT trial findings supporting intensive BP lowering in eligible CKD patients despite renal safety trade-offs.
• Review the ESC (2024) BP classification and apply the ALARA principle to BP targets in CKD.
• Evaluate ACE inhibitors or ARBs as first-line therapy for reducing CV risk and slowing CKD progression.
• Interpret CLICK trial findings on chlorthalidone for resistant hypertension in stage 4 CKD.
• Recognize why ACE inhibitor plus ARB combination therapy should be avoided in CKD.